Prostate-specific membrane antigen (PSMA) PET has become a standard of care for prostate cancer (PCa) imaging, as demonstrated by its inclusion in the most recent guidelines from the National Comprehensive Cancer Network (1). The gene discussed is FOLH1; the disease is prostate cancer.